2-deoxy-2-fluoro-α-D-arabinofuranose 1-phosphate | 850883-62-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-deoxy-2-fluoro-α-D-arabinofuranose 1-phosphate
• 英文别名: 1-phospho-2-deoxy-2-fluoro-α-D-arabinose；α-2d2F-Ara-1-P；2-fluoro-α-D-arabinosyl-1-phosphate；[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl] dihydrogen phosphate
• CAS: 850883-62-4
• 化学式: C₅H₁₀FO₇P
• 分子量: 232.102
• InChiKey: KHZHQHJALVQUPK-KKQCNMDGSA-N

物化性质

• 沸点：
  529.3±60.0 °C(Predicted)
• 密度：
  1.79±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  腺嘌呤 、 2-deoxy-2-fluoro-α-D-arabinofuranose 1-phosphate 在 purine nucleoside phosphorylase 作用下， 以 水 为溶剂， 反应 144.0h， 生成 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
  参考文献：
  名称：

  EP1676853

  摘要：

  公开号：
• 作为产物：
  描述：

  2-deoxy-3,5-di-O-benzoyl-2-fluoro-α-D-arabinofuranosyl-1-phosphate 在 甲醇 、 氨 、 水 作用下， 生成 2-deoxy-2-fluoro-α-D-arabinofuranose 1-phosphate
  参考文献：
  名称：

  EP1676853

  摘要：

  公开号：

文献信息

• New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1
  作者：Maria I. Kharitonova、Alexandra O. Denisova、Valeria L. Andronova、Alexei L. Kayushin、Irina D. Konstantinova、Svetlana K. Kotovskaya、Georgiy A. Galegov、Valery N. Charushin、Anatoly I. Miroshnikov

  DOI：10.1016/j.bmcl.2017.03.100

  日期：2017.6

  Using the enzymatic transglycosylation reaction β-d-ribo- and 2'-deoxyribofuranosides of 2-amino-5,6-difluorobenzimidazole nucleosides have been synthesized. 2-Amino-5,6-difluoro-benzimidazole riboside proved to exhibit a selective antiviral activity (selectivity index >32) against a wild strain of the herpes simplex virus type 1, as well as towards virus strains that are resistant to acyclovir, cidofovir

  使用酶促糖基化反应，已经合成了2-氨基-5,6-二氟苯并咪唑核苷的β-d-核糖-和2'-脱氧核糖呋喃糖苷。事实证明，2-氨基-5,6-二氟苯并咪唑核苷对野生型1型单纯疱疹病毒以及对阿昔洛韦，西多福韦具有抗药性的病毒株表现出选择性的抗病毒活性（选择性指数> 32）和foscarnet。我们相信，在阿昔洛韦无效的情况下，该化合物可用于治疗疱疹感染。
• Gene Therapy of Cancer: Activation of Nucleoside Prodrugs with<i>E. coli</i>Purine Nucleoside Phosphorylase
  作者：John A. Secrist、William B. Parker、Paula W. Allan、L. Lee Bennett、William R. Waud、Jackie W. Truss、Anita T. Fowler、John A. Montgomery、Steven E. Ealick、Alan H. Wells、G. Yancey Gillespie、V. K. Gadi、Eric J. Sorscher

  DOI：10.1080/15257779908041562

  日期：1999.4

  During the last few years, many gene therapy strategies have been developed for various disease targets. The development of anticancer gene therapy strategies to selectively generate cytotoxic nucleoside or nucleotide analogs is an attractive goal. One such approach involves the delivery of herpes simplex virus thymidine kinase followed by the acyclic nucleoside analog ganciclovir. We have developed another gene therapy methodology for the treatment of cancer that has several significant attributes. Specifically, our approach involves the delivery off. coli purine nucleoside phosphorylase, followed by treatment with a relatively non-toxic nucleoside prodrug that is cleaved by the enzyme to a toxic compound. This presentation describes the concept, details our search for suitable prodrugs, and summarizes the current biological data.